y***q 发帖数: 4147 | | t*******o 发帖数: 1464 | 2 6.7-6.8是ASCO会议,期间除BMY等“极个别”股票高涨外,大多数股票两日累计跌幅都
在10%以上,包括有些出positive trial results的股票。CLDX是参会其中之一,具体
cldx的presentation如何,我不清楚。Adam说是asco 生拉集体 sell on news。
【在 y***q 的大作中提到】 : 有人说说吗
| y***q 发帖数: 4147 | 3 哦,那就没关系,你手上还有吗?
【在 t*******o 的大作中提到】 : 6.7-6.8是ASCO会议,期间除BMY等“极个别”股票高涨外,大多数股票两日累计跌幅都 : 在10%以上,包括有些出positive trial results的股票。CLDX是参会其中之一,具体 : cldx的presentation如何,我不清楚。Adam说是asco 生拉集体 sell on news。
| y*****l 发帖数: 5997 | 4 那天很多数据结果好的公司都瀑布了,除了sell on news,还有担心公司被低价收购。
ASCO会议的黑色星期一:ARIA,ARRY,CLDX,OXGN,PCYC...
Celldex also reported data on its metastatic melanoma treatment and a
bladder cancer treatment at the ASCO meeting. Still, shares plunged 19.7% to
$5.27. Celldex declined to comment about the share movement.
Roth analyst, Joseph Pantginis, said it was likely investors were selling on
the news as shares had been up 40% year-to-date before Monday's fall, last
month hitting as high as $9.49. But Pantginis said the reports were very
encouraging, and boosted his price target to $15.
WBB Securities analyst Stephen Brozak said investors might be unwilling to
pile into such an undervalued stock because the low price makes it too easy
of a takeover target. With a market capitalization falling below $200
million Monday and an impressive pipeline, a takeover could come in at a
level well below the $15 Brozak and other analysts think is fair value. That
would reduce the incentive of large investors, Brozak said.
"The real danger here isn't that the company will decline," Brozak said. "
The real danger is the company can get taken out for a price that's way too
cheap."
Other companies sliding on positive headline results included ArQule, whose
shares rose premarket but tumbled 15% to $4.77 in recent action after it
said it had "encouraging" results from a Phase 2 trial involving patients
with non-small-cell lung cancer. Ariad Pharmaceuticals Inc. (ARIA) unveiled
updated data for its treatment for patients with drug-resistant myeloid
leukemia, but slid 5.6% to $3.32 in recent trading.
Pharmacyclics Inc. (PCYC) fell 11.6% to $5.80 after it said its non-Hodgkin'
s Lymphoma treatment showed the drug had "very promising activity and early
signs of efficacy. And Oxigene Inc. (OXGN) saw "positive final data" from
one of its treatments for patients with solid tumors, but dropped 22.7% to
60 cents. | t*******o 发帖数: 1464 | 5 没有,3月份出掉之后就没买过。
我aezs也是周一ASCO大瀑布的时候被stop out的。
【在 y***q 的大作中提到】 : 哦,那就没关系,你手上还有吗?
|
|